Chart Rhythms

Follow the rhythm behind every market move.

News Center

Source articles powering Chart Rhythms.

Browse cached source articles used by the rhythm engine. Filter by ticker, sentiment, or keyword, then open the stock rhythm page for deeper daily, swing, and long-term analysis.

Cached Articles

7738

Tickers With News

507

Showing Now

Top Ticker

Active filters:

Ticker: ABBVSentiment: NEUTRALClear filters

Featured Tickers

Quick rhythm news shortcuts.

Jump straight into the most important tickers for testing and market coverage.

Search all stocks

JPM MA VEEV FICO NVDA AAPL MSFT TSLA

Ticker Filters

Browse by cached coverage.

These are the tickers with the most cached source articles right now.

Search all stocks

All C: 163 TSLA: 159 NVDA: 148 AAPL: 139 F: 138 MSFT: 116 MA: 104 A: 98 JPM: 97

40 source articles found.

Open Markets

ABBVNeutralYahoo • 2026-06-08Cached source

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie's blood cancer portfolio and pipeline include 21 oral and poster presentation

Open Source Open Stock Rhythm

ABBVNeutralBenzinga • 2026-06-08Cached source

Loading Chart Rhythms

Source articles powering Chart Rhythms.

Quick rhythm news shortcuts.

Browse by cached coverage.

40 source articles found.

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades'

Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?

Is AbbVie Stock The Right Defensive Pick In This Volatile Market?

Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?

AbbVie (ABBV) Valuation Check After New Cancer And Migraine Drug Approvals

AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note

AbbVie, Oracle, Apple And More On CNBC's 'Final Trades'

AbbVie (ABBV) Announces European Commission’s Approval of AQUIPTA®

Does Decnupaz Approval Validate ABBV's ADC Strategy in Oncology?

Final Trades: Abbvie, Entegris, Oracle and Apple

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

Final Trades: AbbVie, Goldman Sachs, Old Dominion and the IYE

AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine

Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

AbbVie Inc. (ABBV) Announces EC Authorization of Expanded Label for VENCLYXTO®

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie Says EC Authorizes Expanded Label For VENCLYXTO To Include Use In Combination With Acalabrutinib And Use In Combination With Ibrutinib For The Treatment Of Adult Patients With Previously Untreated Chronic Lymphocytic Leukemia

AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie Inc. (ABBV) Presents at EU Clinical Trial Regulation: Latest Developments and Upcoming Opportunities Transcript

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue?

AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication

Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress

How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds?

ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug

Final Trades: AbbVie, Deckers and Goldman Sachs

Two Paths to Growth: Johnson & Johnson vs AbbVie

What's the Better Dividend Stock Today: AbbVie or Pfizer?

AbbVie Expands European Reach As Investors Weigh Dividend Support

Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

Final trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder

AbbVie cancer trials show responses in lung, prostate and myeloma

AbbVie's MAVIRET Receives Medicinal Products For Human Use's Recommendation Approval To Treat Acute Hepatitis C Infection

AbbVie Inc. (ABBV) Positioned for Long-Term Gains with IBD Pipeline Strength

Laryngeal Cancer Market Research Report 2026-2036, Competitive Analysis of Major Players - Merck & Co., Pfizer, Novartis, and AbbVie

AbbVie's Allergan Aesthetics Receives European Medicines Agency's Committee For Medicinal Products For Human Use's Positive Opinion Recommending Boey For Temporary Improvement In Appearance Of Moderate To Severe Lines Between Eyebrows At Maximum Frown

Hepatic Impairment Market Analysis Report 2026-2036 Featuring AbbVie, Astellas Pharma, Gilead Sciences, F. Hoffmann La Roche, and Takeda Pharmaceuticals